Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants.
about
Screening for hepatitis C virus non-nucleotide resistance mutations in treatment-naive womenEscape of HIV-1 from a small molecule CCR5 inhibitor is not associated with a fitness lossOptimal timing and duration of induction therapy for HIV-1 infectionSimple PCR assays improve the sensitivity of HIV-1 subtype B drug resistance testing and allow linking of resistance mutationsTransmitted drug resistance in the CFAR network of integrated clinical systems cohort: prevalence and effects on pre-therapy CD4 and viral loadHighly-sensitive allele-specific PCR testing identifies a greater prevalence of transmitted HIV drug resistance in JapanVaccination and timing influence SIV immune escape viral dynamics in vivo.Computational models of HIV-1 resistance to gene therapy elucidate therapy design principlesRapid and persistent selection of the K103N mutation as a majority quasispecies in a HIV1-patient exposed to efavirenz for three weeks: a case report and review of the literature.Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients.Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission.Modeling and estimation of kinetic parameters and replicative fitness of HIV-1 from flow-cytometry-based growth competition experiments.Ultrasensitive detection of minor drug-resistant variants for HIV after nevirapine exposure using allele-specific PCR: clinical significance.The non-nucleoside reverse transcriptase inhibitor efavirenz stimulates replication of human immunodeficiency virus type 1 harboring certain non-nucleoside resistance mutations.Estimating frequencies of minority nevirapine-resistant strains in chronically HIV-1-infected individuals naive to nevirapine by using stochastic simulations and a mathematical model.Divergent evolution in reverse transcriptase (RT) of HIV-1 group O and M lineages: impact on structure, fitness, and sensitivity to nonnucleoside RT inhibitors.Human immunodeficiency virus type 1 (HIV-1) integrase: resistance to diketo acid integrase inhibitors impairs HIV-1 replication and integration and confers cross-resistance to L-chicoric acid.Exploring the complexity of the HIV-1 fitness landscape.HIV-1 diversity after a class switch failure.Human immunodeficiency virus type 1 protease inhibitor drug-resistant mutants give discordant results when compared in single-cycle and multiple-cycle fitness assays.Determinants of individual variation in intracellular accumulation of anti-HIV nucleoside analog metabolites.Characterization of the E138K resistance mutation in HIV-1 reverse transcriptase conferring susceptibility to etravirine in B and non-B HIV-1 subtypes.Select resistance-associated mutations in blood are associated with lower CSF viral loads and better neuropsychological performance.Persistence of frequently transmitted drug-resistant HIV-1 variants can be explained by high viral replication capacity.Evaluation of a multiple-cycle, recombinant virus, growth competition assay that uses flow cytometry to measure replication efficiency of human immunodeficiency virus type 1 in cell culture.Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides.Replicative fitness costs of nonnucleoside reverse transcriptase inhibitor drug resistance mutations on HIV subtype C.From resistance to stimulation: the evolution of a virus in the presence of a dominant lethal inhibitory scaffolding protein.HIV Genetic Diversity and Drug Resistance.The fitness cost of mutations associated with human immunodeficiency virus type 1 drug resistance is modulated by mutational interactions.Cross-clade inhibition of recombinant human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus SIVcpz reverse transcriptases by RNA pseudoknot aptamers.Sensitive oligonucleotide ligation assay for low-level detection of nevirapine resistance mutations in human immunodeficiency virus type 1 quasispeciesUltrasensitive allele-specific PCR reveals rare preexisting drug-resistant variants and a large replicating virus population in macaques infected with a simian immunodeficiency virus containing human immunodeficiency virus reverse transcriptase.Clinical significance of human immunodeficiency virus type 1 replication fitness.Impact of novel human immunodeficiency virus type 1 reverse transcriptase mutations P119S and T165A on 4'-ethynylthymidine analog resistance profile.Viral adaptation to an antiviral protein enhances the fitness level to above that of the uninhibited wild typeHuman endothelial cells enhance human immunodeficiency virus type 1 replication in CD4+ T cells in a Nef-dependent manner in vitro and in vivoEvolutionary pathways of transmitted drug-resistant HIV-1.Infection with "escaped" virus variants impairs control of simian immunodeficiency virus SIVmac239 replication in Mamu-B*08-positive macaques.A novel mutation, D404N, in the connection subdomain of reverse transcriptase of HIV-1 CRF08_BC subtype confers cross-resistance to NNRTIs.
P2860
Q27490222-1C282AA8-3C94-4F4A-96B5-B4A597FE5292Q28469223-2C7BA816-CA65-4307-A94C-DE461ADFEEEEQ28469250-CC86E7FD-2DC0-43F5-954F-8EBBE72C42DAQ28469253-C72C2EA8-4533-494D-871F-A37A64D1F72FQ28478656-3FA3E366-E2D1-4561-90FF-3C17F0B4A4F2Q28537608-6F072F5C-BE73-4B0E-8800-82F6570C4449Q33316821-DBC03608-DC92-4CAA-AEC2-AE9953328DC7Q33658642-41EA9E05-07D1-4869-915C-D51C69D60905Q33682067-8019863F-8039-4B9C-9C70-9BDC21B34604Q33714377-3DCF92F6-386D-47BF-9C37-344444A47331Q33739249-84E5F85A-4981-49AD-AB9C-FD5B7E51BD08Q33785915-E7248BCE-EC50-4AEE-89F4-4A21F560FB9DQ33827841-F084CECB-E83E-442C-8E6D-D4711A7F7BEDQ33872810-5715B34F-D1CC-4C4C-9274-30FBAFDC06CBQ34120725-B78E2499-AD4E-4430-927F-2906EBD3B377Q34120878-3C3A78A8-9DD9-4586-81CC-7FFFE01057C2Q34151301-42C178E1-79DB-455C-97B0-E9C39C20772AQ34192888-2BC80674-3826-4F89-BC38-1B1DFA3BEA5AQ34399268-9C07224C-740B-40AF-A349-9DC9FFCFA61CQ34489422-31936B42-9314-4A78-9279-D46CD34B9FB8Q34529268-4228BAC1-78FD-4635-926E-3B527E88584CQ34529310-30A0051A-4C5F-413C-8B2F-EE3158510D7CQ34615228-F6AD4B22-C2F1-4B87-A351-668B8C44CA1DQ34677368-086C8DF5-BB76-4928-84B1-D30A8A76C644Q34719435-5972FCAF-BE59-40E4-8186-DB3E577296D5Q34737547-6EF521C9-F41C-4086-9B20-252824DC79D6Q34933329-E862A8E9-FB92-4F68-83AA-17CAA2C0FD1DQ35077412-00CA231C-436E-4D68-A2AF-8BBE27B87834Q35260590-DA916357-5339-40BD-BA61-C1A27D4B7E5DQ35784897-F864EE51-AF12-47AE-A19D-61ABDC908360Q35857522-18FA3602-EF5E-44E2-997E-532EEA5DC4B5Q35947480-AB4ECE01-9DC9-49DD-9456-07B028745755Q36397557-38779599-8884-4726-8EE5-C95A2A26F7D8Q36969857-9A4903C8-E8D1-423E-B3A9-16313FAA7BB8Q37409900-A3BAA213-5215-4DD0-BB51-9F470BF9A897Q37410676-EE957394-1923-467F-914B-B8BD6F6DF1A2Q37746717-EC06365C-817D-45B8-A35F-9DA240A98233Q37866540-7C520A5C-B566-4429-80C6-6F628A4DF786Q38350825-5B56BF19-FA78-41C0-A8C7-9C4D81F69795Q39627553-2A8BA98B-0013-4CA2-9406-81548E7798A8
P2860
Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants.
@en
type
label
Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants.
@en
prefLabel
Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants.
@en
P2093
P2860
P1433
P1476
Competitive fitness of nevirapine-resistant human immunodeficiency virus type 1 mutants.
@en
P2093
Elijah Paintsil
Jennifer A Collins
Joanna Gedzior
Louis Alexander
M Gregory Thompson
Melisa Ricketts
P2860
P304
P356
10.1128/JVI.78.2.603-611.2004
P407
P577
2004-01-01T00:00:00Z